Combination of VEGF165/Angiopoietin-1 gene and endothelial progenitor cells for therapeutic neovascularization

Chen, Feng; Tan, Zhenhua; Dong, Cheng; Li, Xiong; Xie, Youli; Wu, Yun; Xiao, Chen; Guo, Shiwen

doi:10.1016/j.ejphar.2007.04.047

Cited by 28 publications

(21 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was evidenced by an absence of any signs of neoplastic angiogenesis in the necropsy material. Similar results have been observed by other researchers [11,12,14,15]. However, to evaluate the safety of the Ang-1 plasmid administration, longer observation of a larger group of animals is needed.…”

Section: Discussionsupporting

confidence: 78%

“…A new treatment strategy that aims at the regeneration of endothelial cells uses plasmids encoding proangiogenic cytokines, i.e., the vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF ) and angiopoietin -1(Ang-1) [5,8,11]. Experimental studies suggest that gene therapy can induce vascular growth, cardiomyogenesis and reduce apoptosis and inflammation [5,[11][12][13][14].…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Formation of Blood Vessel After the Administration of the Plasmid Encoding Ang-1 Gene in Fischer Rats

et al. 2016

View full text Add to dashboard Cite

Approximately 1% of patients with peripheral artery disease develop critical lower limb ischemia (CLI) with an unfavorable prognosis. Within one year after the diagnosis, more than 30% of patients with lower limb CLI require amputation [1][2][3][4].The development of endovascular treatment using angioplasty and stents have decreased the amputation rate among patients with CLI. HowCardiovascular disease is the leading cause of death in the Western world and the World Health Organization estimates that over 17 million people worldwide die of cardiovascular disorders each year [1]. There are more than 25 million people in Europe and the United States who have chronic ischemia affecting lower limbs caused by atherosclerotic lesions in the peripheral arteries. A -research concept and design; B -collection and/or assembly of data; C -data analysis and interpretation; D -writing the article; E -critical revision of the article; F -final approval of article AbstractBackground. Chronic limb ischemia is a serious clinical problem. Patients who do not qualify for standard treatment may benefit from novel gene therapies. Objectives. This study evaluated angiogenesis following intramuscular injections of angiogenic plasmid Ang-1 in Fisher rats. Material and Methods. Twenty rats had plasmids injected intramuscularly in their hind limbs. The study group consisted of 10 animals which received the Ang-1 plasmid, while the control group consisted of 10 rats that received an empty plasmid. All the animals were euthanized after 12 weeks and tissue samples from the hind limb thigh muscles and internal organs were harvested for histological and immunohistochemical examinations. To assess the angiogenesis the number of vessels in the hind limb muscles visualized by the SMA and FVIII markers was counted for each animal in five separate microscopic fields. Results. There were no pathological lesions or any signs of neoplastic angiogenesis in any of the 20 rats. The number of vessels visualized by the FVIII marker in the study group was two times higher than in the control group (median: 12, range: 7-25 vs. median: 6, range: 2-15; p < 0.0001). The median estimated that the number of vessels visualized by the SMA marker is 63% higher in the study group compared to the control group (median: 6.5, range: 1-12 vs. median: 4, range: 0-10; p = 0.0008). Conclusions. Intramuscular injections of Ang-1 plasmids induced angiogenesis in the rat hind limb muscles (Adv Clin Exp Med 2016, 25, 4, 611-615).

show abstract

Section: Discussionsupporting

confidence: 78%

mentioning

confidence: 99%

The Formation of Blood Vessel After the Administration of the Plasmid Encoding Ang-1 Gene in Fischer Rats

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Although co-expression of VEGF and ang-1 in ischemic hindlimb and heart has been proven to induce leakage resistant vessels and resulted in some improvements in angiogenesis and therapy (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). Most of the experiments used plasmid as the vector, which only results in short-term gene expression.…”

Section: Discussionmentioning

confidence: 99%

Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart

Takagawa

Huang

et al. 2009

International Journal of Cardiology

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is a key angiogenic factor and has been used experimentally for induction of neovasculature in ischemic myocardium. However, blood vessels induced by VEGF are immature. Angiopoietin-1 (ang-1) has the ability to recruit and sustain periendothelial support cells and promote vascular maturation. Thus, co-expression of the two may yield a better result than expression of either one alone. Two adeno-associated viral vectors (AAV), CMVVEGF and CMVang-1 with the CMV promoter driving VEGF or ang-1 gene expression, respectively, were injected into ischemic mouse hearts individually or together in different ratios. The results show that co-injected groups had more capillaries than the CMVang-1 group and similar densities of capillaries and α-actin positive vessels as the CMVVEGF group. Neovasculature induced by CMVVEGF was leaky. In contrast, neovasculature in CMVang-1-injected or CMVVEGF and CMVang-1 co-injected hearts was less leaky than that in CMVVEGF-injected hearts. The group that received CMVang-1 and CMVVEGF in a 1:1 ratio had the smallest infarct size and best cardiac function and regional wall movement among all the groups. We conclude that ang-1 and VEGF can compensate for each others' shortcomings and yield a better therapeutic effect by acting together.

show abstract

“…The final stage consists in final differentiation into a mature blood vessel and stabilisation [5,6,11]. All the cells participating in the formation of the new blood vessel are stimulated by the vascular endothelial growth factor [13][14][15][16].…”

Section: Discussionmentioning

confidence: 99%

Angiogenesis after plasmid VEGF165 gene transfer in an animal model

Skóra¹,

Barć²,

Dawiskiba³

et al. 2013

cejoi

View full text Add to dashboard Cite

Combination of VEGF165/Angiopoietin-1 gene and endothelial progenitor cells for therapeutic neovascularization

Cited by 28 publications

References 41 publications

The Formation of Blood Vessel After the Administration of the Plasmid Encoding Ang-1 Gene in Fischer Rats

The Formation of Blood Vessel After the Administration of the Plasmid Encoding Ang-1 Gene in Fischer Rats

Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart

Angiogenesis after plasmid VEGF165 gene transfer in an animal model

Contact Info

Product

Resources

About